BRIEF—Sun Pharma to sell Lundbeck's antidepressant in India

Indian drug major Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with Danish CNS specialist Lundbeck to market and distribute its own version of vortioxetine in India.

This drug is an antidepressant with multimodal activity, which is approved to treat major depressive disorder (MDD) in adults. The product is approved in more than 80 countries, including the USA, European Union, Canada and Australia. It is most commonly sold under the brands Trintellix and Brintellix, though Sun Pharma will sell it under the name Vortidif.

Kirti Ganorkar, chief executive of Sun Pharma’s Indian business, said: “Sun Pharma is the leader in neuro-psychiatry therapy in India and we always endeavor to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and Vortidif will serve as an important novel treatment option for patients in India.”